Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy

British Journal of Surgery

Volumn 95, Issue 5, 2008, Pages 611-619

  Tanaka, S ^a   Arii, S ^a   Yasen, M ^a   Mogushi, K ^a   Su, N T ^a   Zhao, C ^a   Imoto, I ^a   Eishi, Y ^b   Inazawa, J ^a   Miki, Y ^a   Tanaka, H ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA B KINASE; AURKB PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RNA; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CHROMOSOME; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; GENE CLUSTER; GENE EXPRESSION; GENETIC ANALYSIS; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENETICS; LIVER TUMOR; METABOLISM; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; GENE EXPRESSION; GENOMIC INSTABILITY; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RETROSPECTIVE STUDIES; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 43549115722     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6011     Document Type: Article

References (31)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524.
3. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K et al. Outcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan criteria: rationale for partial hepatectomy as first strategy. J Am Coll Surg 2007; 204: 1-6.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
5. Shimada M, Takenaka K, Taguchi K, Fujiwara Y, Gion T, Kajiyama K et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 1998; 227: 80-85.
6. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-929.
7. Ho MC, Lin JJ, Chen CN, Chen CC, Lee H, Yang CY et al. A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol 2006; 13: 1474-1484.
8. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
9. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108.
10. Tanaka S, Wands JR. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 1996; 98: 2100-2108.
11. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999; 103: 341-345.
12. Tanaka S, Sugimachi K, Yamashita YI, Ohga T, Shirabe K, Shimada M et al. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002; 35: 861-867.
13. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
14. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
15. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004; 95: 559-563.
16. Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 2005; 96: 100-110.
17. Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63: 2872-2880.
18. Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000; 31: 899-906.
19. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003; 238: 885-893.
20. Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006; 173: 833-837.
21. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis.Mol Biol Cell 2003; 14: 3325-3341.
22. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipll-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998; 58: 4811-4816.
23. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002; 62: 5168-5177.
24. Nguyen HG, Chinnappan D, Urano T, Ravid K. Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol Cell Biol 2005; 25: 4977-4992.
25. Lahad JP, Mills GB, Coombes KR. Stem cell-ness: a 'magic marker' for cancer. J Clin Invest 2005; 115: 1463-1467.
26. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927-936.
27. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003; 161: 281-294.
28. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-267.
29. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007; 50: 2213-2224.
30. Storchova Z, Breneman A, Cande J, Dunn J, Burbank K, O'Toole E et al. Genome-wide genetic analysis of polyploidy in yeast. Nature 2006; 443: 541-547.
31. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006; 119: 3664-3675.